Navigating Procurement of Automated Molecular Diagnostics for HIV Viral Load and Early Infant Diagnosis

The Partnership for Supply Chain Management



November 2023

# The purpose of this document

This document provides a non-technical overview of the diagnostics commonly utilized for HIV viral load tests and early infant diagnosis. It also presents, at a high level, the various modes of procurement for these tests.

## **Glossary**

**Molecular diagnostic -** Test that identifies a pathogen based on the detection of DNA or RNA.

**Platform** - Diagnostic instrument also known by other general terms such as system, analyzer, instrument, or machine.

**Supplier -** Manufacturer of a diagnostic platform and the associated proprietary reagents.

**Polyvalent (multi-disease testing) -** Description of a platform which is able to perform a range of tests based on the supplier's test menu. For example, using the same test platform for HIV and hepatitis C (HCV) testing.

**Consumable** - Generic category of single use, ancillary items which are needed to perform a test (e.g. gloves, tubes, pipette tips, etc.).

**Reagent** - One of the chemicals required to run an assay (test)

**Dried Blood Spot (DBS) -** Dried whole blood sample from a finger stick or infant's heel stick.

**cobas Plasma Separation Card (PSC)** – Roche's proprietary product for preserving plasma for molecular diagnostics from a small volume of whole blood.

**Sputum** – A sample of saliva and mucus coughed up from the respiratory tract often used for tuberculosis testing.

**Polymerase Chain Reaction (PCR)** – Chemical process used to copy DNA in a sample to enable detection. A variation known as Reverse Transcription (RT-PCR) is used to detect RNA targets.

**Extraction** - Process of removing the DNA or RNA from a pathogen in a sample to enable subsequent PCR or RT-PCR.

**Viral Load (VL) -** The amount of virus in a sample. Commonly measured by PCR or RT-PCR.

**Early Infant Diagnosis (EID)** - Qualitative, PCR-based test to diagnose children between 6 weeks and 18 months of age.

**Incoterm** - Definition of shipping and trade terms published by the International Chamber of Commerce (ICC) to ensure clarity and consistency in international trade agreements.




### What are automated molecular diagnostics?


Molecular diagnostics identify a pathogen by detecting the pathogen's DNA or RNA. The detection of viral RNA (or DNA) is referred to as a Viral Load (VL) test.

HIV VL tests are sometimes referred to simply as "viral load" because HIV VL tests were historically the first VL tests widely available in low- and middle- income countries (LMICs). Early Infant Diagnosis (EID) of HIV can utilize the same platforms used for adult HIV VL.

Automated molecular diagnostics are centralized, lab-based platforms with a high volume of tests per day (throughput). However near-point-of-care (nPOC), community-based automated platforms having a lower throughput are also used. These platforms are polyvalent, meaning that they can be used for multi-disease testing such as HIV, EID, SARS-CoV-2, tuberculosis (TB), hepatitis C (HCV), human papillomavirus (HPV), etc. depending on the supplier's test portfolio



### There are a range of procurement modes for HIV VL and EID tests



#### OPPORTUNITIES AND CHALLENGES OF PROCUREMENT MODALITIES FROM PERSPECTIVE OF PRINCIPLE RECIPIENT

#### **Opportunities Challenges** • Flexibility without volume commitments. • Requires the individual purchase of the platform, • May offer value when there is a significant reagents and consumables. **Direct** existing platform install base. • May be less cost effective than more inclusive modes **Purchase** • When "all-inclusive" eligibility requirements of procurement. can not be met. • Limited cost component visibility due to hidden costs compared to more inclusive modes of procurement. • Annual payments are made (often to the • Minimum test volume thresholds or other local distributor) for the use of a platform. commitments from the recipient may apply. • Combine multiple cost components such as: • Minimum test volumes thresholds are required. service and maintenance, loading from warehouse local agent fees, etc. • Utilize more inclusive incoterms than direct purchase. "All-inclusive" • May include the placement of a platform Procurement at no additional cost. • KPIs that the supplier agrees to meet (e.g. time to respond to a service request. • May help streamline procurement.

## **Detailed comparison of modes of procurement**

	Direct Purchase	Hybrid Example	All-Inclusive
Volume commitment			<b>✓</b>
Instrument placed at no additional cost		<b>✓</b>	<b>~</b>
Reagents and propriety consumables purchased directly	<b>~</b>	<b>✓</b>	<b>✓</b>
Service and maintenance (S&M)		<b>✓</b>	<b>~</b>
Invalid results due to instrument errors replaced			<b>~</b>

 $<sup>\</sup>hbox{*Inclusion of components in these examples may vary for each mode of procurement}$ 

## THERE IS NO ONE-SIZE FITS ALL MODE OF PROCUREMENT WHICH IS BEST FOR ALL SCENARIOS

## Some key considerations and questions for the recipient:

- 1 Inclusive agreements require test volume commitments.
- 2 Is there an existing footprint of a particular supplier's platforms?
- 3 Is testing integrated across disease programs to maximize testing volumes and enable volume thresholds to be met?
- 4 Are diagnostic networks optimized for maximum utilization of platforms?
- B Has a procurement modality cost assessment been performed, which includes in-country cost components such distributor mark-ups?
- 6 Are there legacy direct purchase platforms which could be transitioned to inclusive agreements?



pfscm@pfscm.org | www.pfscm.org | +1-571-227-8600

2733 Crystal Drive, 4th Floor Arlington, VA 22202

